Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COLSTENT
2023-508935-30-00Phase 3Authorised
- Sponsor
- Uniwersytecki Szpital Kliniczny w Opolu
- Start
- Apr 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of colchicine in lower extremity arterial disease (LEAD), sponsored by Uniwersytecki Szpital Kliniczny w Opolu. Primary endpoints: Patency of the superficial femoral artery at 24 months and Overall risk assessment of the procedure. Planned start Apr 2024; status: authorised.
02
Drugs
colchicine
03
Conditions
lower extremity arterial disease (LEAD)
Beyond the preview
Go deeper on 2023-508935-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508935-30-00.